secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2025-07-14T23:59:59+00:00
Accession:  0001641172-25-018894
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré's Ovaprene Phase 3 interim shows ~9% pregnancy rate; DSMB OK to continue
-----------------------------------------------------------------------------

- DSMB recommended study continue without modification after planned interim safety analysis.
- ~9% of treated women had experienced a pregnancy, consistent with company expectations.
- ~17% discontinued due to vaginal odor; no serious safety concerns or new tolerability issues.
- ~115 of target ~250 participants ongoing/completed; final primary endpoint uses Pearl Index.
- Bayer can obtain U.S. commercialization rights with $20M payment, plus up to $310M milestones and tiered royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000164117225018894/0001641172-25-018894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000164117225018894/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-018894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer